1167 Stock Overview
An investment holding company, engages in the in-house discovery and development of oncology therapies.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Jacobio Pharmaceuticals Group Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.82 |
52 Week High | HK$4.57 |
52 Week Low | HK$1.38 |
Beta | 0.56 |
11 Month Change | 5.20% |
3 Month Change | 4.60% |
1 Year Change | -49.16% |
33 Year Change | -90.22% |
5 Year Change | n/a |
Change since IPO | -87.38% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation
May 31Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?
May 29We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely
May 10Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook
Aug 26We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate
Jul 29We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth
Apr 29What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?
Mar 21Shareholder Returns
1167 | HK Biotechs | HK Market | |
---|---|---|---|
7D | -19.5% | -10.1% | -6.2% |
1Y | -49.2% | -4.2% | 17.6% |
Return vs Industry: 1167 underperformed the Hong Kong Biotechs industry which returned -4.2% over the past year.
Return vs Market: 1167 underperformed the Hong Kong Market which returned 17.6% over the past year.
Price Volatility
1167 volatility | |
---|---|
1167 Average Weekly Movement | 10.7% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 8.7% |
10% most volatile stocks in HK Market | 18.5% |
10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1167 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1167's weekly volatility (11%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 298 | Yinxiang Wang | www.jacobiopharma.com |
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company’s drug development programs include Glecirasib (JAB-21822), a KRAS G12C inhibitor currently under multiple stage studies for indications, including NSCLC, PDAC, CRC and other solid tumors; JAB-3068, an SHP2 inhibitor approved by the FDA to enter clinical development for the treatment of esophageal cancer, including esophageal squamous cell carcinoma; and JAB-3312, an SHP2 inhibitor with multiple indications, such as KRAS G12C mut NSCLC under Phase III pivotal study, and Osimertinib progressed NSCLC under Phase I study, as well as NSCLC, HNSCC, and ESCC under Phase IIa studies. It also develops JAB-23E73 currently under IND-enabling studies for targeting multiple KRAS mutants indicated for PDAC, CRC, and NSCLC; JAB-BX300, a self-developed LIF mAb, under IND study indicated for the treatment of solid tumors; JAB-22000, a small-molecule KRAS G12D inhibitor, under lead optimization study indicated for PDAC, CRC, and NSCLC treatments; and JAB-8263, a Bromodomain and Extra-Terminal motif (BET) inhibitor, under Phase I studies indicated for MF, AML, and solid tumor.
Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary
1167 fundamental statistics | |
---|---|
Market cap | HK$1.44b |
Earnings (TTM) | -HK$397.95m |
Revenue (TTM) | HK$25.50m |
56.3x
P/S Ratio-3.6x
P/E RatioIs 1167 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1167 income statement (TTM) | |
---|---|
Revenue | CN¥23.19m |
Cost of Revenue | CN¥22.38m |
Gross Profit | CN¥801.00k |
Other Expenses | CN¥362.69m |
Earnings | -CN¥361.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.46 |
Gross Margin | 3.45% |
Net Profit Margin | -1,560.88% |
Debt/Equity Ratio | 7.0% |
How did 1167 perform over the long term?
See historical performance and comparison